Pasar al contenido principal


Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting

Noticias

Dr. Reddy's Pioneers Pharma Advancements Through Strategic Partnerships and Innovation: A Glimpse into Vision 2030: Growth Trajectory and Opportunities for Indian Pharma

In a recent contribution to the Citeline CEO Conclave's white paper on "Vision 2030: Growth Trajectory and Opportunities for Indian Pharma," Kalpeshkumar N. Modi, Vice President and Regional Sales Head at Dr. Reddy's Laboratories, highlighted the company's strategic moves towards innovation and collaboration in the pharmaceutical industry.

During the challenging times of the Covid-19 pandemic, Dr. Reddy's actively pursued in-licensing and partnering opportunities, demonstrating substantial momentum. Notable collaborations include agreements with Eli Lilly for baricitinib, MSD for Molnupiravir, and, more recently, partnerships with Chinese company Pregene for an anti- BCMA CAR-T cell therapy injection designed for multiple myeloma. Additionally, the company entered into agreements with Wellington Zhao Tai Therapies for an exclusive license to its CAR-T cell technology.

Dr. Reddy's commitment to expanding its therapeutic portfolio is evident in in-licensing deals with Jiangsu Hengrui Pharmaceuticals Co., Ltd for a breast cancer therapy called pyrotinib, and with Shanghai Junshi Biosciences Co. Ltd. to develop and commercialise toripalimab, an anti-PD-1 monoclonal antibody, across 21 countries. The company's B2B initiatives focus on fostering direct partnerships to support big pharma in product lifecycle management and collaborating with smaller companies engaged in drug development under the 505(b)(2) approval process.

Known for its leadership in digitisation efforts to enhance productivity and foster continuous improvement, Dr. Reddy's is also capitalising on CDMO opportunities. The company's subsidiary, Aurigene Pharmaceutical Services, is dedicated to discovery, development, and manufacturing for global R&D-driven biopharma companies. This involves building value-added partnerships, such as those aimed at developing cell and gene therapies, reducing the cost of CAR T-cell therapy, and innovating therapeutic solutions.

“We are continuing to work toward strengthening our position as a partner of choice,” said Kalpeshkumar N. Modi, Vice President, and Regional Sales Head of Dr. Reddy’s Laboratories.

White Paper Link - https://bit.ly/3uMkwfJ

Contact Us

Rellene el siguiente formulario y nos pondremos en contacto con usted a la brevedad.

Nuestra lienea de contacto email: api@drreddys.com | +91 40 49002222

Renuncia

Ninguna información en este sitio web, incluyendo cualquier referencia a cualquier producto o servicio, constituye una oferta de venta ni se interpretará como tal. Los productos protegidos por patentes válidas no se ofrecen ni suministran para uso comercial. Sin embargo, en ciertos casos, a discreción exclusiva de Dr. Reddy's y sujeto a los requisitos legales locales, las cantidades de investigación de dichos productos pueden ofrecerse para fines de presentaciones regulatorias según la Sección 107A de la Ley de Patentes de la India (exención de Bolar), donde existan dichas exenciones regulatorias. Los compradores deben realizar su propia evaluación del producto o servicio, incluyendo el escenario de patentes en sus respectivos mercados, y serán responsables de todas las responsabilidades relacionadas con las patentes. Dr. Reddy's renuncia a todas las garantías, expresas o implícitas, incluyendo, entre otras, las garantías de comerciabilidad, idoneidad para un propósito particular y no infracción.

Empresa

Contactenos

Follow Us on

  • Twitter

Dr. Reddy’s Laboratories, 8-2-337,
Banjara Hills Rd Number 3,
SBI Executive Enclave, Green Valley,
Banjara Hills, Hyderabad,
Telangana 500034
Phone: 040 4900 2222

© 2025 Dr. Reddy’s Laboratories Ltd. All rights reserved.

Dr. Reddy’s Laboratories, 8-2-337,
Banjara Hills Rd Number 3,
SBI Executive Enclave, Green Valley,
Banjara Hills, Hyderabad,
Telangana 500034
Phone: 040 4900 2222

  • Twitter

© 2025 Dr. Reddy’s Laboratories Ltd.
All rights reserved.